avian
flu
pandem
drug
could
use
treat
prevent
infect
influenza
viru
foremost
viral
neuraminidas
inhibitor
oseltamivir
zanamivir
alreadi
use
treat
human
influenza
b
viru
infect
use
ion
channel
blocker
amantadin
rimantadin
compound
rapid
develop
drug
resist
although
formal
approv
indic
ie
treatment
hepat
c
ribavirin
pegyl
interferon
might
also
use
control
avian
flu
combin
use
current
avail
drug
taken
account
attempt
made
develop
new
strategi
direct
unexplor
target
viral
protein
hemagglutinin
viral
polymeras
endonucleas
nonstructur
protein
shown
viral
infect
rna
interfer
could
power
mean
suppress
replic
avian
outbreak
avian
influenza
southeast
asia
increas
geograph
distribut
epizoot
viru
abil
transfer
human
caus
sever
infect
ie
pneumonia
arous
seriou
concern
regard
control
measur
undertaken
curb
potenti
pandem
diseas
wake
pandem
sever
prevent
therapeut
strategi
formul
promin
stockpil
neuraminidas
inhibitor
particular
oseltamivir
current
avian
origin
hong
kong
spread
bird
southeast
asia
countri
occasion
transmiss
human
human
case
half
fatal
whether
current
avian
evolv
caus
pandem
either
mutat
current
viru
antigen
drift
reassort
avian
influenza
viru
human
nonavian
influenza
viru
antigen
shift
unpredict
present
recent
review
antivir
agent
activ
influenza
virus
could
use
either
therapeut
andor
prophylact
influenza
viru
pandem
whether
human
avian
equin
porcin
address
strategi
could
undertaken
target
could
envisag
combat
avian
infect
specif
replic
cycl
human
avian
influenza
virus
follow
similar
scenario
figur
bind
sialic
acid
receptor
influenza
virion
intern
receptormedi
endocytosi
low
ph
endosom
trigger
fusion
viral
endosom
membran
influx
h
channel
releas
viral
rna
gene
cytoplasm
uncoat
adamantan
deriv
block
uncoat
step
rna
replic
transcript
step
requir
repeat
cycl
rna
rna
polymer
reaction
occur
nucleu
block
indirectli
inosin
monophosph
imp
dehydrogenas
inhibitor
eg
ribavirin
suppress
biosynthesi
gtp
directli
rna
polymeras
inhibitor
eg
translat
viral
mrna
protein
could
prevent
interferon
small
interf
si
rna
packag
bud
virion
occur
cytoplasm
membran
neuraminidas
inhibitor
block
releas
newli
form
virion
infect
cell
antiinfluenzaviru
compound
current
avail
antivir
drug
still
develop
divid
differ
class
accord
molecular
target
interact
neuraminidas
inhibitor
eg
zanamivir
oseltamivir
peramivir
ii
ion
channel
blocker
eg
amantadin
rimantadin
iii
imp
dehydrogenas
inhibitor
eg
ribavirin
viramidin
iv
interferon
sirna
v
rna
polymeras
endonucleas
inhibitor
eg
flutimid
repres
congen
belong
class
ii
iii
v
shown
figur
wherea
viral
hemagglutinin
ha
need
influenza
viru
interact
receptor
bear
nacetylneuramin
acid
nana
sialic
acid
viral
neuraminidas
cleav
nana
enabl
progeni
virion
leav
infect
cell
spread
host
cell
block
releas
viru
particl
neuraminidas
inhibitor
prevent
spread
viru
neuraminidas
inhibitor
oseltamivir
receiv
attent
drug
stockpil
therapeut
use
human
infect
avian
flu
given
eas
administr
oral
mg
twice
daili
five
day
system
avail
oseltamivir
certainli
recommend
drug
choic
use
ignor
howev
use
oseltamivir
lead
develop
resist
resist
oseltamivir
clinic
isol
human
influenza
associ
mutat
posit
neuraminidas
particular
mutat
associ
resist
human
influenza
viru
oseltamivir
recent
resist
oseltamivir
shown
caus
mutat
patient
oseltamivirresist
strain
isol
recov
diseas
viru
found
less
pathogen
ferret
parent
strain
howev
two
patient
mutant
viru
isol
oseltamivir
treatment
die
infect
indic
possibl
associ
mutat
death
interestingli
probenecid
found
prevent
renal
secret
parent
compound
oseltamivir
oral
prodrug
form
thu
markedli
increas
system
exposur
oseltamivir
combin
oseltamivir
probenecid
might
import
therapeut
option
sever
ill
patient
might
enabl
use
standard
dose
mg
twice
daili
oseltamivir
current
recommend
studi
highli
pathogen
strain
mice
could
infer
prolong
oseltamivir
regimen
ie
eightor
tenday
rather
fiveday
treatment
higher
dose
mg
instead
mg
twice
daili
might
requir
benefici
antivir
effect
altern
intraven
administr
oseltamivir
might
consid
therapeut
option
particularli
sever
ill
patient
current
avail
neuraminidas
inhibitor
zanamivir
must
administ
inhal
devic
low
system
avail
zanamivir
follow
administr
includ
low
drug
level
lower
respiratori
tract
replic
current
virus
seem
take
place
howev
zanamivir
activ
oseltamivirresist
variant
although
yet
demonstr
avian
influenza
neuraminidasebas
resist
like
develop
oseltamivir
zanamivir
combin
two
drug
might
consid
corrobor
resist
pattern
zanamivir
oseltamivir
overlap
need
urgent
eg
sever
ill
patient
zanamivir
oseltamivir
administ
parenter
ie
intramuscularli
intraven
henc
adequ
formul
made
avail
purpos
sever
neuraminidas
inhibitor
peramivir
describ
interestingli
peramivir
proven
effect
panel
five
zanamivirresist
six
oseltamivirresist
influenza
b
virus
indic
resist
neuraminidas
inhibitor
might
overlap
also
structur
influenza
neuraminidas
recent
resolv
help
ration
design
inhibitor
initi
clinic
studi
oral
administr
peramivir
offer
robust
protect
infect
human
influenza
viru
studi
parenter
formul
peramivir
warrant
meanwhil
longact
dimer
inhibitor
influenza
viru
neuraminidas
develop
offer
prospect
new
type
antiinfluenza
drug
could
administ
onceweekli
dose
prevent
infect
antivir
agent
neuraminidas
inhibitor
potenti
control
prevent
therapi
influenza
infect
adamantan
deriv
amantadin
rimantadin
specif
activ
influenza
interfer
viral
uncoat
process
direct
interact
matrix
protein
function
channel
hydrogen
ion
proton
amantadin
rimantadin
howev
notori
rapidli
lead
drug
resist
compromis
potenti
use
use
singl
agent
treatment
infect
concern
highlight
recent
data
adamantan
resist
among
influenza
virus
isol
usa
worldwid
concern
regard
potenti
use
adamantan
deriv
influenza
two
clade
current
circul
virus
clade
vietnam
thailand
cambodia
clade
indonesia
whole
clade
amantadin
resist
drug
resist
also
note
strain
clade
sever
new
adamantan
deriv
effect
influenza
synthes
howev
compound
yet
evalu
activ
virus
broadspectrum
antivir
agent
ribavirin
use
inhibitor
influenza
b
viru
infect
year
ribavirin
particularli
activ
rna
virus
includ
orthomyxovirus
paramyxovirus
paramyxoviru
respiratori
syncyti
viru
rsv
rna
viru
infect
ribavirin
formal
approv
aerosol
although
oral
ribavirin
success
treatment
influenza
infect
use
combin
inject
pegyl
ainterferon
treat
hepat
c
viru
hcv
infect
recent
viramidin
carboxamidin
analogu
ribavirin
shown
similar
efficaci
ribavirin
influenza
viru
infect
consid
lower
toxic
viramidin
might
warrant
evalu
possibl
therapi
influenza
viru
includ
infect
iron
interferon
discov
almost
year
ago
influenza
viru
induc
fact
baron
isaac
describ
absenc
interferon
lung
fatal
case
influenza
sinc
interferon
use
come
long
way
pegyl
ainterferon
combin
ribavirin
becom
standard
therapi
hcv
infect
therefor
extens
experi
accumul
combin
could
readili
implement
therapi
avian
flu
durat
treatment
would
much
shorter
hcv
use
interferon
prophylaxi
treatment
influenza
one
howev
take
account
fact
interferon
alon
might
caus
flulik
symptom
base
principl
rna
interfer
sirna
specif
highli
conserv
region
viral
nucleoprotein
acid
polymeras
found
protect
mice
lethal
influenza
viru
ie
challeng
vivo
deliveri
system
compat
human
use
demonstr
potenti
use
sirna
prophylaxi
therapi
influenza
viru
infect
human
similarli
sirna
proven
power
new
mean
combat
respiratori
viru
infect
involv
rsv
sever
acut
respiratori
syndrom
sar
ten
year
ago
fluoroguanosin
describ
inhibitor
influenza
viru
transcript
although
studi
capac
also
substitut
pyrazin
report
potent
vitro
activ
influenza
b
c
effect
oseltamivir
protect
mice
experiment
infect
influenza
yet
evalu
avian
consid
target
action
assum
effect
pyrazin
appar
recogn
cellular
enzym
nucleobas
convert
triphosph
metabolit
turn
inhibit
viral
polymeras
polymeras
inhibitor
expect
resist
profil
overlap
known
influenza
viru
inhibitor
anoth
possibl
select
inhibit
influenza
viru
replic
target
capdepend
endonucleas
activ
polymeras
complex
sever
inhibitor
influenza
endonucleas
eg
flutimid
report
select
inhibitor
influenza
viru
b
replic
develop
view
need
addit
drug
might
seem
mandatori
explor
viral
polymeras
andor
endonucleas
antivir
target
recent
new
compound
thiadiazolo
pyrimidin
pyrimidinyl
acylthiourea
report
inhibit
influenza
viru
replic
low
mm
concentr
howev
mechan
target
action
compound
elucid
addit
sialidas
fusion
protein
fludas
report
subnanomolar
concentr
inhibit
human
avian
influenza
viru
replic
potenti
fludas
topic
treatment
influenza
viru
infect
remain
establish
plausibl
yet
proven
option
prophylaxi
treatment
influenza
viru
infect
combin
pegyl
interferon
ribavirin
could
complement
amantadin
rimantadin
tripledrug
combin
shown
efficaci
review
trend
pharmacolog
scienc
vol
treatment
hcv
infect
might
worth
explor
treatment
andor
prevent
influenza
viru
infect
even
base
current
avail
drug
sever
doubl
tripleand
quadrupledrug
combin
could
envisag
prevent
treatment
avian
figur
includ
combin
oseltamivir
zanamivir
resist
profil
overlap
partial
combin
neuraminidas
inhibitor
ion
channel
blocker
extens
combin
includ
pegyl
interferon
ribavirin
compound
shown
figur
activ
influenza
differ
mechan
might
combin
synerg
antivir
action
reduc
risk
emerg
drugresist
viru
variant
addit
viral
rna
polymeras
andor
endonucleas
mention
earlier
potenti
target
new
antiinfluenzaviru
agent
clue
regard
virul
virus
human
could
consid
point
attack
chemotherapeut
intervent
first
amino
acid
posit
viral
polymeras
protein
mutat
glutam
acid
lysin
virus
might
repres
adapt
virus
effici
replic
mammalian
cell
second
ha
virus
contain
unusu
stretch
basic
amino
acid
rrrkkrg
cleav
ubiquit
intracellular
proteas
includ
furin
recombin
virus
lack
basic
amino
acid
virul
mice
third
ctermin
domain
nonstructur
protein
avian
virus
contain
sequenc
motif
esevepev
consid
virul
factor
bind
human
host
protein
disrupt
morpholog
function
ferret
howev
ctermin
sequenc
requir
virul
virus
therefor
role
esevepev
motif
molecular
determin
virul
virus
must
explor
sever
drug
avail
could
use
either
alon
combin
prophylaxi
treatment
influenza
pandem
includ
compound
alreadi
use
influenza
viru
infect
amantadin
rimantadin
zanamivir
oseltamivir
addit
compound
use
infect
virus
ribavirin
pegyl
interferon
use
treat
hcv
attempt
design
develop
new
antivir
drug
intensifi
whether
base
known
molecular
target
neuraminidas
andor
viral
uncoat
process
rel
unexplor
target
viral
endonucleas
viral
rna
polymeras
principl
could
target
nucleosid
nonnucleosid
inhibitor
latter
approach
thought
analog
nucleosid
nonnucleosid
inhibitor
hiv
revers
transcriptas
hcv
rna
polymeras
six
medic
journal
publish
launch
health
internetwork
access
research
initi
enabl
nearli
world
poorest
countri
gain
free
access
biomed
literatur
internet
scienc
publish
blackwel
elsevi
harcourt
worldwid
stm
group
wolter
kluwer
intern
health
scienc
springerverlag
john
wiley
approach
british
medic
journal
initi
journal
made
avail
free
significantli
reduc
price
univers
medic
school
research
public
institut
develop
countri
addit
publish
join
journal
avail
current
publish
particip
program
gro
harlem
brundtland
former
directorgener
said
initi
perhap
biggest
step
ever
taken
toward
reduc
health
inform
gap
rich
poor
countri
inform
visit
wwwwhointhinari
review
